Arya Amini, M.D. | City of Hope

Dr. Arya Amini

Claim this profile

City of Hope Medical Center

Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
9 reported clinical trials
22 drugs studied

Area of expertise

1

Lung Cancer

Arya Amini has run 7 trials for Lung Cancer. Some of their research focus areas include:

Stage IV
EGFR positive
Stage III
2

Non-Small Cell Lung Cancer

Arya Amini has run 4 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:

Stage IV
EGFR positive
Stage III

Affiliated Hospitals

Image of trial facility.

City Of Hope Medical Center

Image of trial facility.

City Of Hope Comprehensive Cancer Center

Clinical Trials Arya Amini is currently running

Image of trial facility.

SBRT Guided by PET Scans

for Non-Small Cell Lung Cancer

This phase II trial tests the safety of positron emission tomography (PET) guided stereotactic body radiation therapy (SBRT) and how well it works to treat non-small cell lung cancer (NSCLC), melanoma, and renal cell carcinoma (RCC) that has up to 5 sites of progression (oligoprogression) compared to standard SBRT. SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. A PET scan is an imaging test that looks at your tissues and organs using a small amount of a radioactive substance. It also checks for cancer and may help find cancer remaining in areas already treated. Using a PET scan for SBRT planning may help increase the dose of radiation given to the most resistant part of the cancer in patients with oligoprogressive NSCLC, melanoma, and RCC.

Recruiting

1 award

Phase 2

12 criteria

Image of trial facility.

Geriatric Assessment

for Lung Cancer

This clinical trial tests how well a geriatric assessment (GA) with GA-directed treatment recommendations, compared to GA with usual care, works in identifying risk factors, reducing chemotherapy radiation toxicity and functional decline, and improving the overall quality of life in older patients with non-small cell lung cancer (NSCLC). Older patients with lung cancer undergoing chemotherapy are at an increased risk of adverse outcomes including treatment toxicity and functional and physical consequences. This makes it very challenging for the physicians to balance the benefits against the risk of chemotherapy in older cancer patients. A geriatric assessment may be useful in identifying risk factors for chemotherapy radiation toxicity. Communicating these geriatric assessment findings and assessment-based recommendations to a patient's treating physicians may help them make more informed decisions about treatment options for patients. Making treatment decisions using GA-based recommendations may reduce adverse events and improve outcomes in patients receiving treatment for NSCLC.

Recruiting

1 award

N/A

10 criteria

More about Arya Amini

Clinical Trial Related

2 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 5 Active Clinical Trials

Treatments Arya Amini has experience with

  • Stereotactic Body Radiation Therapy
  • Atezolizumab
  • Carboplatin
  • Cemiplimab
  • Biologically Guided Radiation Therapy (BgRT)
  • Osimertinib

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Arya Amini specialize in?

Is Arya Amini currently recruiting for clinical trials?

Are there any treatments that Arya Amini has studied deeply?

What is the best way to schedule an appointment with Arya Amini?

What is the office address of Arya Amini?

Is there any support for travel costs?